Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-Iso-prostaglandin F2α (8-iso-PGF2α) level in patients with inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 16, Issue 1, 2010, Pages 52-57

  Owczarek, Danuta ^a   Cibor, Dorota ^a   Mach, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Crohn's disease; Endothelial dysfunction; Oxidative stress; Ulcerative colitis

Indexed keywords

6 N,N' DIMETHYLARGININE; 8 ISOPROSTAGLANDIN F2 ALPHA; ARGININE; ARGININE DERIVATIVE; C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; N(G),N(G) DIMETHYLARGININE; STEROID;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; SEX RATIO; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DINOPROST; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; YOUNG ADULT;

EID: 74049159439     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20994     Document Type: Article

References (34)

1. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol. 2004;20:311-317.
2. Torres MI, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol. 2008;14:1972-1980.
3. Abreu MT, Sparrow MP. Translational research in inflammatory bowel disease. Mt Sinai J Med. 2006;78:1067-1072.
4. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94.
5. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
6. Shanahan F. Inflammatory bowel disease; immunodiagnostics, immunotherapeutic and ecotherapeutics. Gastroenterology. 2001;120:622-636.
7. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807-4812.
8. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43:542-548.
9. Bäger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med. 2003;41:1467-1472.
10. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.
11. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Phrmacol Ther. 2002;16:1997-2015.
12. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015-2021.
13. Grune T, Berger MM. Markers of oxidative stress in ICU clinical settings: present and future. Curr Opin Clin Nutr Metab Care. 2007;10:712-717.
14. Stenson WF. Inflammatory bowel diseases. In: Yamada T, ed. Textbook of Gastroenterology, Vol. 2, 2nd ed. Philadelphia: JB Lippincott; 1995:1761-1772.
15. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal Classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
16. Rentsch M, Beham A, Schlitt HJ, et al. Crohn's Disease Activity Index and Vienna Classification - is it worthwhile to calculate before surgery? Dig Surg. 2006;4:241-249.
17. van Deventer SJ, Tami JA, Wedel MK, and European Colitis Study Group.A randomized, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53:1646-1651.
18. Yimaz MI, Sonmez A, Saglam M, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol. 2008;19:388-395.
19. Teerlik T, Nijveldt RJ, de Jong S, et al. Determination of arginine, asymmetric dimethylarinine, and symmetric dymeticarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002;303:131-137.
20. Yasuda S, Miyzaki S, Kanada M, et al. Intensive treatment of risk factor in patients with typ-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J. 2006;27:1159-1165.
21. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005;10:11-17.
22. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol. 2004;20:7B-19B.
23. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep. 2006;58:159-178.
24. Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69.
25. Horowitz S, Binion DG, Nelson VM, et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2007;292:1323-1336.
26. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun. 2000;275:715-719.
27. Iwashita E, Miyahara T, Hino K, et al. High nitric oxide synthase activity in endothelial cells in ulcerative colitis. J Gastroenterol. 1995;30:551-554.
28. Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:179-189.
29. Li J, Zhou Z, Jiang DJ, et al. Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine. Clin Exp Hypertens. 2007;29:489-501.
30. Maor I, Rainis T, Lanir A, et al. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53:2208-2214.
31. Krzystek-Korpacka M, Neubauer K, Berdowska I, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis. 2008;14:794-802.
32. Wendland BE, Aghdassi T, Tam C, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr. 2001;74:259-264.
33. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction. Circulation. 1999;99:3092-3095.
34. Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201:28-36.